.png){kind=icon}
Return
Data management and sharing
.png){kind=icon}
OA
AI
DOI：10.1016/j.jclinepi.2025.111680.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Guided by the FAIR principles (Findable, Accessible, Interoperable, Reusable), responsible data sharing requires well-organized, high-quality datasets. However, researchers often struggle with implementing Data Management and Sharing Plans due to lack of knowledge on how to do this, time constraints, and legal, technical, and financial challenges, particularly concerning data ownership and privacy. While patients support data sharing, researchers and funders may hesitate, fearing the loss of intellectual property or competitive advantage. Although some journals and institutions encourage or mandate data sharing, further progress is needed. Additionally, global solutions are vital to ensure equitable participation from low- and middle-income countries. Ultimately, responsible data sharing requires strategic planning, cultural shifts in research, and coordinated efforts from all stakeholders to become standard practice in biomedical research. (c) 2025 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
Keywords:
Data sharing
Data management
Clinical trials
Ethics
Integrity
Open science
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5.2
Papers:
8.5K
Citations:
4.3W
Organization
No organization information available
Cited Papers
Implementing clinical trial data sharing requires training a new generation of biomedical researchers.png)
NATURE MEDICINE
OAAI
NATURE MEDICINEIF50
OAAIShareSaveUnderstanding the provenance and quality of methods is essential for responsible reuse of FAIR dataNATURE MEDICINE
NATURE MEDICINEIF50
PREAI
ShareSaveShareSaveVibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysisBMJ MEDICINEOAAI
BMJ MEDICINEIF10
OAAIShareSaveShareSaveShareSave
View more